Guangzhou Maange Cosmetics Co., Ltd. – Trademark Portfolio
Entity Type: 16
Guangzhou Maange Cosmetics Co., Ltd. owns a portfolio of 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as MSVO, AWVUQ, MAGEFY, and BRETEIL. Of these, 5 are registered and 1 is pending. The portfolio spans 4 Nice Classification classes, led by Class 3 (Cosmetics & Cleaning) and Class 21 (Housewares). Headquartered in Guangzhou.
Room 4#408, Building E,Tai'an
Cosmetics Market, Sanyuanli, Baiyun
Guangzhou 510000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Guangzhou Maange Cosmetics Co., Ltd.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Guangzhou Maange Cosmetics Co., Ltd. have?
Guangzhou Maange Cosmetics Co., Ltd. has 7 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 pending, 1 abandoned.
What trademark classes does Guangzhou Maange Cosmetics Co., Ltd. file in?
Guangzhou Maange Cosmetics Co., Ltd. files trademarks across 4 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 21 (Housewares), Class 25 (Clothing), Class 24 (Fabrics). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Guangzhou Maange Cosmetics Co., Ltd.'s most well-known trademarks?
Guangzhou Maange Cosmetics Co., Ltd.'s registered trademark portfolio includes well-known marks such as MSVO, AWVUQ, MAGEFY, and BRETEIL. These are among 5 currently registered trademarks in the portfolio.
What is Guangzhou Maange Cosmetics Co., Ltd.'s trademark registration success rate?
Guangzhou Maange Cosmetics Co., Ltd. has a 83% trademark registration rate, with 5 out of 6 resolved applications resulting in successful registration. Currently, 1 application is pending review.